# TORNTPHARM (TORNTPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/torntpharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹4,860.5
- Change: -0.30%
- As of: 2026-09-18
- 1D return: -0.72%
- 5D return: -1.83%
- 1M return: -3.30%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, TORNTPHARM is trading at ₹4840.0. The stock exhibits a mixed technical stance across different timeframes. Daily indicators suggest a weakening trend, with the price below key moving averages like the 20-day EMA (₹4911.72) and 50-day SMA (₹4946.57), despite the Supertrend indicator remaining bullish. However, weekly and monthly timeframes show stronger alignment with bullish trends, indicated by the price trading above multiple moving averages and a bullish Supertrend signal on both periods. Recent market activity includes two high-participation anomalies in the past week: a high-volume, directionless move on September 16, 2026, and an upward gap on September 10, 2026. The stock is currently positioned near its nearest support level at ₹4834.15, which is approximately 0.12% below the current price, and faces resistance around ₹4856.17, about 0.33% higher. The stock's current drawdown stands at -0.06%, with annualized volatility at 0.22.

- Daily indicators show price below 20-day EMA (₹4911.72) and 50-day SMA (₹4946.57), while weekly and monthly trends remain bullish.
- Nearest support is observed at ₹4834.15 (0.12% below current price), with resistance at ₹4856.17 (0.33% above current price).
- A high-participation, directionless anomaly occurred on September 16, 2026, with volume 2.25 times the average.
- The active daily Harami pattern on September 18, 2026, warrants monitoring for potential trend continuation or reversal.
- Watch for a sustained break below ₹4834.15 support or a move above ₹4856.17 resistance for directional confirmation.

- Harami
- Bullish Engulfing Reversal
- Inside Bar
- Outside Bar

### News Context

Strides Pharma was mentioned in a report on the Bandhan Small Cap Fund's August portfolio changes. The fund, which saw the highest inflows among small-cap schemes in August at ₹2,187 crore, increased its holdings in Strides Pharma. This fund activity suggests a positive sentiment from at least one institutional investor towards the company during August. Separately, the broader Indian pharmaceutical market demonstrated sustained growth in August, driven by price increases and new product introductions. However, the sector faces challenges including weak sales volumes and uncertainty related to US tariffs, which could impact sustained margin recovery.

- Bandhan Small Cap Fund increased its holdings in Strides Pharma in August 2026.
- The Bandhan Small Cap Fund received ₹2,187 crore in inflows in August 2026, the highest among small-cap schemes.
- The domestic pharmaceutical market showed growth in August 2026 due to price hikes and new launches, but faces margin pressures from weak volumes and US tariff uncertainty.

- Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint
- Domestic pharma market sustains growth momentum, but margins remain key

### What Changed

As of September 18, 2026, Torrent Pharmaceuticals (TORNTPHARM) on the NSE saw a slight decrease in its stock price, closing at ₹4840.0 compared to its previous price of ₹4875.0. The available evidence does not indicate any new filings or news developments for the company around this observation date. The company's profile and exchange listing on the NSE remain unchanged from earlier context.

- On September 18, 2026, TORNTPHARM's stock closed at ₹4840.0 on the NSE.
- This represents a decrease from the previous price of ₹4875.0.
- No new filings or news were reported for TORNTPHARM as of September 18, 2026.
- The company continues to be listed on the NSE.

### Official Filings

Torrent Pharmaceuticals Limited has announced its participation in several investor meetings scheduled for September 2026. Representatives will attend the Jefferies India forum in Gurgaon on September 17, 2026, the Kotak Healthcare Forum in Mumbai on September 18, 2026, and the JP Morgan India Conference in Mumbai on September 21, 2026. These engagements provide opportunities for the company to communicate its strategy and performance to institutional investors and analysts.

Additionally, the company has confirmed the appointment of Shanti Ekambaram as an Independent Director, following shareholder approval via a postal ballot. The resolution received overwhelming support, with 99.98% of valid votes cast in favor. This appointment is for a three-year term commencing July 30, 2026. The company also received an Environmental, Social, and Governance (ESG) rating of 70 from NSE Sustainability Ratings and Analytics Limited on August 11, 2026.

- Investor meetings scheduled: Jefferies India forum (Sep 17, 2026), Kotak Healthcare Forum (Sep 18, 2026), JP Morgan India Conference (Sep 21, 2026).
- Shanti Ekambaram appointed as Independent Director following shareholder approval via postal ballot.
- The special resolution for Shanti Ekambaram's appointment received 34,13,59,869 'for' votes (99.98%) and 81,679 'against' votes (0.02%).
- Shanti Ekambaram's tenure as Independent Director is effective from July 30, 2026, to July 29, 2029.
- Received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited on August 11, 2026.

- Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares |SUBJECT: Copy of Newspaper Publication
- Torrent Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot |SUBJECT: Shareholders meeting
- Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Torrent Pharmaceuticals Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL

### Fundamentals

Torrent Pharmaceuticals reported a sequential increase in revenue from operations, rising from ₹3,303 crore in Q3 FY2025-26 to ₹4,921 crore in Q1 FY2026-27. This revenue growth was accompanied by a rise in Profit Loss For Period (PAT), which increased from ₹635 crore in Q3 FY2025-26 to ₹566 crore in Q1 FY2026-27. However, the company's Profit Before Tax (PBT) showed a decline between Q3 FY2025-26 (₹814 crore) and Q4 FY2025-26 (₹529 crore), before recovering to ₹733 crore in Q1 FY2026-27. An increase in Finance Costs, from ₹45 crore in Q3 FY2025-26 to ₹305 crore in Q1 FY2026-27, was observed. Expenses also rose sequentially from ₹2,466 crore in Q3 FY2025-26 to ₹4,155 crore in Q1 FY2026-27, impacting profitability margins.

Key monitoring areas include the trend in finance costs and the company's ability to translate revenue growth into improved profit margins, given the rise in expenses. Investors should also monitor the trajectory of Profit Before Tax and Profit Loss For Period in the upcoming quarters.

- Revenue from operations increased sequentially from ₹3,303 crore in Q3 FY2025-26 to ₹4,921 crore in Q1 FY2026-27.
- Profit Loss For Period (PAT) was ₹635 crore in Q3 FY2025-26 and ₹566 crore in Q1 FY2026-27.
- Profit Before Tax (PBT) declined from ₹814 crore in Q3 FY2025-26 to ₹529 crore in Q4 FY2025-26, recovering to ₹733 crore in Q1 FY2026-27.
- Finance Costs increased from ₹45 crore in Q3 FY2025-26 to ₹305 crore in Q1 FY2026-27.
- Expenses rose sequentially from ₹2,466 crore in Q3 FY2025-26 to ₹4,155 crore in Q1 FY2026-27.

### Bull Case

Torrent Pharmaceuticals' technical indicators show a generally constructive setup across multiple timeframes. The monthly trend is bullish, supported by a Supertrend indicator at ₹3,817.42 and a strong positive reading on the Plus DI (28.9) compared to the Minus DI (7.66), indicating upward momentum. This bullish sentiment extends to the weekly timeframe, where the Supertrend is also bullish at ₹4,275.64, with the Plus DI (22.82) exceeding the Minus DI (9.4). While the daily trend shows some mixed signals with the EMA 20 slope being negative, the overall Supertrend direction remains bullish at ₹4,705.97, and the SMA 50 slope is positive (2.61), suggesting underlying support. The company has also demonstrated significant long-term returns, with a return of 36% over the past year and 26% year-to-date as of the trade date.

- Monthly Supertrend indicator is bullish at ₹3,817.42, with a Plus DI of 28.9 and Minus DI of 7.66.
- Weekly Supertrend indicator is bullish at ₹4,275.64, with a Plus DI of 22.82 and Minus DI of 9.4.
- Daily Supertrend indicator is bullish at ₹4,705.97, and the SMA 50 slope is positive at 2.61.
- The company has achieved a 36% return over the last year and a 26% return year-to-date.

- Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint
- Domestic pharma market sustains growth momentum, but margins remain key

### Bear Case

The company's stock is trading below key short-term moving averages, indicating potential near-term weakness. Specifically, the closing price of ₹4840.0 is below the 20-day Exponential Moving Average (EMA) of ₹4911.72 and the 20-day Simple Moving Average (SMA) of ₹4926.85. The daily trend indicators, such as the ADX at 12.98, suggest a lack of strong directional momentum. While the monthly trend shows a bullish supertrend direction, the monthly ADX at 63.27 indicates significant volatility. The stock has experienced a current drawdown of -6% and a maximum drawdown of -15%, suggesting periods of notable decline from recent highs.

- As of 2026-09-18, the stock price of ₹4840.0 is below the 20-day EMA of ₹4911.72 and the 20-day SMA of ₹4926.85.
- The daily ADX_14 is 12.98, suggesting weak directional trend on a daily basis.
- The stock has experienced a current drawdown of -6% and a maximum drawdown of -15%.
- The monthly ADX_14 is 63.27, indicating high volatility on a monthly basis.

- Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint
- Domestic pharma market sustains growth momentum, but margins remain key

### FAQs

**What recent corporate actions has Torrent Pharmaceuticals undertaken?**

Torrent Pharmaceuticals has announced several corporate actions. On September 7, 2026, the company reported that a special resolution to appoint Shanti Ekambaram as an Independent Director was passed via postal ballot, with 99.98% of valid votes in favor. On August 11, 2026, the company received an Environmental, Social, and Governance (ESG) Rating of 70 from NSE Sustainability Ratings and Analytics Limited. Additionally, the company dispatched a Postal Ballot Notice on August 5, 2026, and published related newspaper advertisements on the same date.

**What is Torrent Pharmaceuticals' recent stock performance and technical trend?**

As of September 18, 2026, Torrent Pharmaceuticals has shown varied returns across different periods. The stock has returned 36% over the last year and 26% year-to-date. However, recent short-term returns show a decline, with a 1% decrease in the last day, a 3% decrease over the last month, and a 2% decrease over the last 5 days. Technically, the daily trend shows a closing price of ₹4840.0, with the 20-day Exponential Moving Average (EMA) at ₹4911.72, indicating the current price is below this short-term average. The supertrend indicator on the daily chart is bullish at ₹4705.97. On a monthly basis, the supertrend indicator is also bullish at ₹3817.42, with a strong ADX of 63.27 suggesting a significant trend.

**What upcoming investor events has Torrent Pharmaceuticals scheduled?**

Torrent Pharmaceuticals representatives are scheduled to participate in three investor meetings in September 2026. These include the Jefferies India forum in Gurgaon on September 17, 2026, the Kotak Healthcare Forum in Mumbai on September 18, 2026, and the JP Morgan India Conference in Mumbai on September 21, 2026. The company noted that these schedules are subject to change.

- Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint
- Domestic pharma market sustains growth momentum, but margins remain key
- Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication Newspaper advertisement in respect of special window for transfer and dematerialization requests of physical shares |SUBJECT: Copy of Newspaper Publication
- Torrent Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot |SUBJECT: Shareholders meeting
- Torrent Pharmaceuticals Limited has informed the Exchange about General Updates |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹4,856.17
- Risk regime: Price Risk Currently Contained

### Support levels
- 4834.15
- 4259.2
- 4237.44375

### Resistance levels
- 5032.33125
- 5250
- 4917.833333333334

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.72% |
| return_10 | -1.34% |
| return_1m | -2.64% |
| return_1y | +35.67% |
| return_20 | -3.30% |
| return_3m | +8.87% |
| return_5 | -1.83% |
| return_6m | +12.84% |
| return_since_start | +41.58% |
| return_ytd | +25.77% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -14.86% |
| annualized_volatility | +22.04% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Surges 55% Year-on-Year, but Pre-Tax Profit Nearly Flat as Finance Costs Surge

Torrent Pharmaceuticals reported a 55% year-on-year increase in revenue for the first quarter of FY2026-27, reaching ₹4,921 crore. However, profit before tax remained nearly flat at ₹733 crore, as total expenses grew even faster (73% YoY) and finance costs surged more than fivefold. A larger deferred tax credit helped net profit rise modestly.

## Revenue and Expense Growth

Revenue from operations was ₹4,921 crore in Q1 FY2026-27, up 54.85% from ₹3,178 crore in the same quarter last year. Sequentially, revenue grew 17.25% from ₹4,197 crore in Q4 FY2025-26. Total expenses rose 72.91% YoY to ₹4,155 crore, outpacing revenue growth. Finance costs were a notable component of the expense increase, rising from ₹56 crore to ₹305 crore.

## Finance Costs

Finance costs increased to ₹305 crore in Q1 FY2026-27, compared to ₹56 crore in Q1 FY2025-26, a rise of 444.64%. This sharp increase was a major factor limiting profit growth.

## Profitability and Tax

Profit before exceptional items and tax was ₹754 crore, up 2.17% YoY. Profit before tax was ₹733 crore, essentially flat YoY (down 0.68%). Net profit for the period was ₹566 crore, up 3.28% YoY. The tax expense decreased to ₹167 crore from ₹190 crore last year, primarily due to a larger deferred tax credit of ₹87 crore (compared to ₹11 crore credit last year), which offset a higher current tax charge of ₹254 crore (up 26.37% YoY).

## Comprehensive Income and Earnings Per Share

Comprehensive income for the period was ₹645 crore, up 18.13% YoY, benefiting from positive other comprehensive income of ₹79 crore, a reversal from negative OCI in the year-ago quarter. Basic earnings per share from continuing operations was ₹14.87, down 8.15% YoY from ₹16.19.

## Key Takeaway

Torrent Pharmaceuticals delivered a substantial increase in revenue, but the benefit was largely absorbed by a sharp rise in expenses, particularly finance costs. Profit before tax remained nearly flat year-on-year, while net profit increased modestly due to a larger deferred tax credit. The quarter highlights top-line expansion with cost pressures, especially interest expenses, limiting bottom-line growth.

### Ratios

## Official filings

- 2026-09-10 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_10092026212728_SE10062026.pdf)
- 2026-09-09 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_09092026174816_SE.pdf)
- 2026-09-07 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_07092026200322_SE.pdf)
- 2026-08-11 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_11082026145119_ESG.pdf)
- 2026-08-06 — Generic Announcement: Torrent Pharmaceuticals Limited completed the dispatch of Postal Ballot Notice on August 5, 2026, to members registered as of July 31, 2026. Newspaper advertisements regarding this dispatch were published on August 5, 2026, in the Financial Express (English & Gujarati). — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_06082026141407_SE_Intimation_-_Advt_Postal_Ballot_Notice.pdf)
- 2026-08-05 — Official Filing: Torrent Pharmaceuticals Limited will hold a shareholders meeting via postal ballot on August 8, 2026, at 09:00 AM in Ahmedabad. The meeting will consider the appointment of Shanti Ekambaram as an Independent Director, with her tenure starting July 30, 2026, and ending July 29, 2029. The postal ballot voting period concludes on September 6, 2026.
- 2026-08-05 — Generic Announcement: Torrent Pharmaceuticals Limited is conducting a postal ballot via e-voting from August 8, 2026, to September 6, 2026, to seek shareholder approval for the appointment of Shanti Ekambaram as an Independent Director for a three-year term effective July 30, 2026. The results will be announced by September 8, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_05082026174349_SE_Intimation_-_Postal_Ballot_Notice__002_.pdf)
- 2026-08-04 — Generic Announcement: Torrent Pharmaceuticals Limited has placed the transcript of its conference call with analysts and investors regarding the financial results for the quarter ended June 30, 2026, on its website. This disclosure was made on August 4, 2026, in accordance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_04082026122506_SE_Intimation_-_Transcript.pdf)
- 2026-08-04 — Generic Announcement: Torrent Pharmaceuticals Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_305_WebXMLFile_20260804_125112621.xml)
- 2026-08-01 — Generic Announcement: Ameera Shah ceased to be an Independent Director of Torrent Pharmaceuticals Limited on August 1, 2026, upon completion of her term. This follows an earlier intimation dated July 30, 2026, and is in accordance with SEBI Listing Regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_01082026212618_SE_Intimation_Ameera_Shah.pdf)
- 2026-08-01 — Official Filing: Torrent Pharmaceuticals Limited reported that Ms. Ameera Shah, a Non-Executive Independent Director, completed her tenure on August 1, 2026. This change in management is effective as of the same date.
- 2026-07-30 — Press Release: Torrent Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on July 30, 2026. The company reported consolidated revenues of Rs. 4,921 crores, a 55% year-over-year increase, with a Net Profit After Tax of Rs. 566 crores. The Board also approved the financial results and noted that Independent Director Ameera Shah will complete her term on August 1, 2026. The financial results reflect the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with the company, effective January 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_30072026165229_SE.pdf)
- 2026-07-30 — Official Filing: Torrent Pharmaceuticals Limited submitted a statement for the quarter ended June 30, 2026, detailing the utilization of issue proceeds and any deviations. The filing indicates there were no deviations or variations in the use of funds raised for listed non-convertible securities.
- 2026-07-30 — Generic Announcement: Torrent Pharmaceuticals Limited has placed an audio recording of its conference call with analysts and investors regarding the financial results for the quarter ended June 30, 2026, on its website. This follows a previous communication dated July 17, 2026, and complies with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_30072026192712_Audio_recording.pdf)
- 2026-07-30 — Generic Announcement: Torrent Pharmaceuticals Limited announced that Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni have ceased to be part of Senior Management Personnel effective July 30, 2026, due to a change in reporting structure. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_30072026170150_SMP.pdf)
- 2026-07-30 — Generic Announcement: Torrent Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on July 30, 2026. The company reported consolidated revenues of Rs. 4,921 crores, a 55% year-over-year increase, with a Net Profit After Tax of Rs. 566 crores. The Board also approved the financial results and noted that Independent Director Ameera Shah will complete her term on August 1, 2026. The financial results reflect the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) with the company, effective January 21, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_30072026164928_SE.pdf)
- 2026-07-28 — Official Filing: Torrent Pharmaceuticals Limited appointed Shanti Ekambaram as a Non-Executive Non-Independent Director for a term of 36 months, effective July 30, 2026. Ms. Ekambaram, aged 63, brings 39 years of financial services experience, including a 35-year tenure at Kotak Mahindra Bank, where she held the position of Deputy Managing Director and Whole-time Director from 2022 to 2025. She is not related to any other director of the company and is not debarred from holding office by any SEBI order or other authority.
- 2026-07-28 — Management Change: Torrent Pharmaceuticals Limited's Board of Directors has approved the appointment of Shanti Ekambaram as an Additional Independent Director, effective July 30, 2026, for a three-year term, subject to shareholder approval. Ms. Ekambaram, aged 63, brings 39 years of financial services experience, including a significant tenure at Kotak Mahindra Bank, and is not related to any existing company directors. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_28072026093711_SE_Intimation_Appointment_of_ID.pdf)
- 2026-07-27 — Generic Announcement: Torrent Pharmaceuticals Limited received final listing and trading approval from NSE and BSE on July 27, 2026, for 4,19,22,416 fully paid-up equity shares. These shares were issued and allotted pursuant to the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited. The shares will be listed and admitted to dealings on both exchanges effective July 28, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_27072026190626_SE_Trading_approval.pdf)
- 2026-07-20 — Generic Announcement: Torrent Pharmaceuticals Limited has approved the allotment of 4,19,22,416 fully paid-up equity shares to eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited as of July 17, 2026. This allotment is part of the sanctioned Scheme of Amalgamation between the two companies, effective July 20, 2026. The allotment will increase Torrent Pharma's issued and paid-up equity share capital from ₹1,69,22,27,200 to ₹1,90,18,39,280. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_20072026124412_SE_Intimation_Allotment_of_shares.pdf)
- 2026-07-17 — Generic Announcement: Torrent Pharmaceuticals Limited announced the voluntary dissolution of its wholly owned subsidiary, Curatio Inc., in the Philippines, effective July 10, 2026. The company received confirmation of this dissolution on July 17, 2026. For the financial year ending March 31, 2026, Curatio Inc. contributed nil turnover and had a net worth of Rs 1.3 Crores, representing 0.02% of the parent company's net worth. The dissolution was achieved through an amendment to the subsidiary's Articles of Incorporation, not a sale. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_17072026224140_SE_Intimation_Curatio_Inc.pdf)
- 2026-07-17 — Generic Announcement: Torrent Pharmaceuticals Limited received an ESG rating of 'Crisil ESG 66' and a Core ESG rating of 'Crisil Core ESG 74' from Crisil ESG Ratings & Analytics Limited on July 17, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/TORNTPHARM_17072026223743_SEIntimationESGRating1707.pdf)

## News and market events

- 2026-09-17 — Mint: **Bandhan Small Cap Fund August portfolio: Cyient, P N Gadgil see higher holdings; 4 stocks added, 6 exited | Mint** — Bandhan Small Cap Fund attracted ₹2,187 crore in August, the highest inflow among small-cap schemes, as it reshuffled several existing holdings and added four new stocks. Cyient, P N Gadgil Jewellers and Strides Pharma were among the stocks where holdings increased. — [Source](https://www.livemint.com/money/personal-finance/bandhan-small-cap-fund-august-portfolio-cyient-p-n-gadgil-see-higher-holdings-4-stocks-added-6-exited-11789636919234.html)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms)
- 2026-08-20 — CNBC-TV18: **Ruby Mills sells 33rd-floor commercial space at The Ruby to Torrent Pharma for ₹124 crore** — Shares of The Ruby Mills Ltd ended at ₹412.80, up by ₹1.15, or 0.28%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/ruby-mills-share-price-sells-33rd-floor-commercial-space-at-the-ruby-to-torrent-pharma-for-rs-124-crore-19973774.htm)
- 2026-07-31 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty hits 24,400 mark; market at day's high** — Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-infosys-banks-tata-steel-swiggy-sun-pharma-mdl-bajaj-fin-share-price-liveblog-19958369.htm)
- 2026-07-31 — The Hindu: **Q1 Results Today Live: Maruti Suzuki, Sun Pharma, Bajaj Finserv, ITC, IOC, Dixon, Bajaj Holdings, ABB India, Kirloskar Brothers, BlueDart, Glenmark, Aether to announce Q1 results, Bajaj Finance, M&M, Hyundai shares up, Vedanta & Tata Steel flat, Swiggy declines, Thermax drags after Q1** — Q1 Results Today, 31st July 2026 Live Updates: Stay tuned for more from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-maruti-suzuki-sun-pharma-dixon-tech-bajaj-holdings-abb-india-kirloskar-brothers-bluedart-glenmark-pharma-bajaj-finserv-itc-ioc-aether-ind-results-31-july-2026/article71285346.ece)
- 2026-07-31 — MONEYCONTROL: **Buzzing Stocks | RailTel slips 3% on mixed Q1 earnings; Astra Microwave gains 12% on ₹2,205 crore HAL order** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/buzzing-stocks-railtel-corporation-falls-3-on-mixed-earnings-astra-microwave-surges-2-on-hal-order-of-2-205cr-13989653.html)
- 2026-07-31 — BUSINESSTODAY: **Top stocks in news: Tata Steel, Bajaj Finance, Swiggy, Mazagon, RailTel, LIC Housing, Medanta** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Bajaj Finance, Swiggy, Tata Steel, Mazagon Dock Shipbuilders, Torrent Pharmaceuticals, LIC Housing Finance, AWL Agri Business, RailTel Corporation of India, Aarti Industries, Indegene, Global Health, Chambal Fertilisers & Chemicals, Thermax, Data Patterns (India), Rainbow Children's Medicare, Satin Creditcare Network, GNG Electronics, MOIL, Nucleus Software Exports — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-tata-steel-bajaj-finance-swiggy-mazagon-railtel-lic-housing-medanta-546413-2026-07-31)
- 2026-07-30 — Mint: **Domestic focus powers Torrent, Mankind in June quarter | Company Business News** — India-focused drugmakers outpaced US-facing peers as strong domestic demand and acquisitions drove double-digit June-quarter growth. — [Source](https://www.livemint.com/companies/company-results/domestic-focus-powers-torrent-mankind-in-june-quarter-medicine-pharma-merger-growth-acquisition-11785423266899.html)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: RailTel profit flat, JBM Auto margin expands** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)
- 2026-07-22 — Times of India: **Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%** — India Business News: Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, r. — [Source](https://timesofindia.indiatimes.com/business/india-business/pharma-stocks-bleed-after-trump-announces-upto-200-tariff-on-generic-drugs/articleshow/132551541.cms)
- 2026-07-22 — Economic Times: **Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028** — Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption before imposing steep duties from 2028. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-cipla-other-pharma-stocks-in-focus-as-trump-unveils-100-200-tariffs-on-generic-drugs-from-2028/articleshow/132550249.cms)
- 2026-07-22 — News18: **Dr Reddy, Aurobindo, Cipla: Pharma Stocks To Remain In Focus Today After Trump's New Generic Drugs Tariff Plan** — Imported generic medicines will remain tariff-free for two years from August 1, after which the US plans to impose a 100% duty for one year and a 200% tariff thereafter. — [Source](https://www.news18.com/business/markets/dr-reddy-aurobindo-cipla-pharma-stocks-to-remain-in-focus-today-after-trumps-new-generic-drugs-tariff-plan-ws-l-10226357.html)
- 2026-07-22 — CNBC-TV18: **Donald Trump to impose 100% tariff on generic pharma imports from 2028, 200% a year later** — Trump's earlier tariffs in this sector pertained to branded and patented drugs, the policy of which has been left unchanged. The earlier policy had left out generic drugs, as nearly 90% of the US prescriptions comprise of them. — [Source](https://www.cnbctv18.com/market/sun-pharma-lupin-cipla-biocon-share-price-donald-trump-generic-drugs-tariffs-timeline-impact-19950953.htm)
- 2026-07-20 — Mint: **Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street** — Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each. — [Source](https://www.livemint.com/market/stock-market-news/cipla-ajanta-pharma-to-alkem-laboratories-pharma-stocks-rise-amid-weak-trends-on-dalal-street-11784531087488.html)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical products globally.

### Business segments
- **Cardiovascular:** Focuses on the development and sale of pharmaceutical products within the cardiovascular therapeutic area.
- **Central Nervous System:** Focuses on the development and sale of pharmaceutical products within the central nervous system therapeutic area.
- **Gastro-intestinal:** Focuses on the development and sale of pharmaceutical products within the gastro-intestinal therapeutic area.
- **Diabetology:** Focuses on the development and sale of pharmaceutical products within the diabetology therapeutic area.
- **Anti-infective:** Focuses on the development and sale of pharmaceutical products within the anti-infective therapeutic area.
- **Pain Management:** Focuses on the development and sale of pharmaceutical products within the pain management therapeutic area.
- **Nephrology:** Has a presence in the nephrology segment.
- **Oncology:** Has a presence in the oncology segment.
- **Gynecology:** Has a presence in the gynecology segment.
- **Respiratory:** Has a presence in the respiratory segment.
- **Pediatrics:** Has a presence in the pediatrics segment.
- **Vaccines and Diagnostics:** Involves the development and selling of specialized products like vaccines and diagnostics.
- **Other Products:** Includes pharmaceuticals, generic drugs, over-the-counter drugs, contact lenses, and animal health products.

### Competitive strengths
- Global presence in over 40 countries
- More than 2,000 product registrations globally
- Operations across multiple key therapeutic areas

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/torntpharm
Markdown representation: https://faxioms.com/stocks/torntpharm?render=md